

pyridinium benzenesulfonate

(2-{5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-trimethyl-ammonium 2-hydroxy-ethanesulfonate

5 (2-{5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-trimethyl-ammonium methanesulfonate


(2-{5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-

10 trimethyl-ammonium chloride

and pharmaceutically acceptable salts thereof.

8. A compound as claimed in any of claims 1 to 7 which is a compound of formula (I)' where the absolute configuration of carbon (1) is that shown here below:

15



and wherein R₁, R₂, R₃, B and A are as defined for compounds of formula (I).

9. A compound as claimed in any of claims 1 to 8, in the form of a
20 pharmaceutically acceptable salt.

10. A pharmaceutical composition comprising a compound as claimed in any of
| claims 1 to 9 and a pharmaceutically acceptable carrier or excipient.

25 11. A pharmaceutical composition as claimed in claim 10 which is adapted for oral administration or administration by the pulmonary route.

12. A compound as claimed in any of claims 1 to 9 for the treatment of, ~~or for use in the manufacture of a medicament for use in the treatment of,~~ a disease or condition in which HNE is implicated.

5 13. ~~— A method of treatment of a disease or condition in which HNE is implicated, comprising administering to a subject suffering such disease an effective amount of a compound as claimed in any of claims 1 to 9.~~

10 ~~13~~14. A compound for use according to claim 12, ~~or a method of treatment according to claim 13,~~ wherein the disease or condition is chronic obstructive pulmonary disease (COPD), bronchiectasis, chronic bronchitis, lung fibrosis, pneumonia, acute respiratory distress syndrome (ARDS), pulmonary emphysema, smoking-induced emphysema or cystic fibrosis.

15 ~~14~~15. A compound for use according to claim 12 ~~or a method of treatment according to claim 13,~~ wherein the disease or condition is asthma, rhinitis, psoriasis, atopic dermatitis, non-atopic dermatitis, Crohn's disease, ulcerative colitis, or irritable bowel disease.

20 15. Use of a compound as claimed in any of claims 1 to 9 in the manufacture of a medicament for the treatment of a disease or condition in which HNE is implicated.

25 16. The use according to claim 15, wherein the disease or condition is chronic obstructive pulmonary disease (COPD), bronchiectasis, chronic bronchitis, lung fibrosis, pneumonia, acute respiratory distress syndrome (ARDS), pulmonary emphysema, smoking-induced emphysema or cystic fibrosis.

30 17. The use according to claim 15, wherein the disease or condition is asthma, rhinitis, psoriasis, atopic dermatitis, non-atopic dermatitis, Crohn's disease, ulcerative colitis, or irritable bowel disease.